What is EBITDA?

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is calculated by taking net income and adding back interest expense, income tax provision, depreciation, and amortization. Alternatively, it can be calculated as operating income plus depreciation and amortization. EBITDA strips out financing, tax, and non-cash accounting decisions to reveal the core cash-generating ability of a business's operations.

EBITDA is widely used in corporate finance for valuation multiples (particularly EV/EBITDA), merger and acquisition analysis, and debt covenant calculations. It serves as a rough proxy for operating cash flow, though it does not account for capital expenditures, changes in working capital, or actual tax payments. Despite its limitations, EBITDA remains the most commonly referenced profitability metric in earnings calls, analyst reports, and financial media.

Adjusted EBITDA, which further excludes one-time or non-recurring items like restructuring charges, stock-based compensation, and impairments, is the metric most frequently highlighted by cannabis company management teams. While adjusted EBITDA can provide useful insight into ongoing operational performance, investors should scrutinize what is being adjusted and whether the excluded items are truly non-recurring. Some companies exclude so many items that adjusted EBITDA bears little resemblance to actual profitability.

For cannabis companies, positive adjusted EBITDA is a key milestone on the path to profitability. Many operators have achieved positive adjusted EBITDA even while reporting negative net income due to 280E taxes, interest costs, and non-cash charges. Investors should track EBITDA margin (EBITDA / Revenue) over time to assess whether a company is improving its operational efficiency as it scales.

When analyzing ebitda for cannabis stocks, investors must account for industry-specific factors that can distort this metric compared to other sectors. Section 280E tax treatment dramatically impacts profitability metrics for US plant-touching operators, potentially making profitable companies appear unprofitable on paper. Additionally, the rapid growth phase of the cannabis industry means that historical comparisons within the sector itself may be limited.

Cannabis companies often report both GAAP and adjusted financial figures, and ebitda may differ significantly between the two. Investors should understand which version is being presented and what adjustments have been made. Comparing ebitda across cannabis sub-sectors (MSOs vs. LPs vs. ancillary companies) requires additional context because each faces different regulatory environments, tax treatments, and competitive dynamics.